Summary of CDC consultations related to nontraditional therapies and settings, 2016–2023
Authors:
- 24 November 2025
- journal article
- research article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (2) , 175-179
Abstract
Objective and Design: Therapies provided in nontraditional settings or by individuals without knowledge of core principles of infection prevention and control (IPC) may place consumers at risk of adverse events. We summarize findings from our recent consultation experiences in the Division of Healthcare Quality Promotion (DHQP) at the Centers for Disease Control and Prevention (CDC) to help identify targets for prevention efforts and enhanced consumer protections. Methods: We reviewed records of DHQP consultations with state, local, or territorial health officials conducted from 2016 to 2023 to identify investigations involving nontraditional therapies or settings in the United States. Information collected included type of procedure or therapy, type of setting, pathogens involved, number of affected individuals, and types of IPC issues identified. Results: Of 1500 consultations, we identified 30 (2%) involving nontraditional therapies or settings. Therapies were performed for esthetic reasons, general wellness, or as treatment for pain. Infectious pathogens were identified in the blood, joint fluid, and skin and soft tissue, and included viruses, bacteria, and fungi. Investigations revealed breaches in injection safety, medical device reprocessing, medication preparation and handling, and environmental disinfection. Over 7000 consumers received notification regarding potential exposure to an infectious pathogen. Conclusions: This summary highlights the potential infectious risks to consumers posed by nontraditional therapies, which may have unproven benefits and poorly defined risks. With continued expansion of nontraditional therapies and settings, consumers will benefit from education, training, and oversight of those who provide therapies in these settings.Keywords
This publication has 9 references indexed in Scilit:
- Notes from the Field: Illnesses After Administration of Presumed Counterfeit Botulinum Toxin in Nonmedical Settings — Tennessee and New York City, March 2024MMWR. Morbidity and Mortality Weekly Report, 2024
- Investigation of Presumptive HIV Transmission Associated with Receipt of Platelet-Rich Plasma Microneedling Facials at a Spa Among Former Spa Clients — New Mexico, 2018–2023MMWR. Morbidity and Mortality Weekly Report, 2024
- The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventionsCell Stem Cell, 2021
- Characterizing healthcare delivery in the United States using Census Bureau’s County Business Patterns (2000–2016)Infection Control & Hospital Epidemiology, 2020
- Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood–Derived Stem Cell Products for Other Than Hematopoietic or Immunologic Reconstitution — United States, 2018MMWR. Morbidity and Mortality Weekly Report, 2018
- The US Direct-to-Consumer Marketplace for Autologous Stem Cell InterventionsPerspectives in Biology and Medicine, 2018
- Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMDNew England Journal of Medicine, 2017
- Health Care–Associated Infection Outbreak Investigations in Outpatient Settings, Los Angeles County, California, USA, 2000−2012Emerging Infectious Diseases, 2015
- A Large Outbreak of Hepatitis B Virus Infections Associated With Frequent Injections at a Physician's OfficeInfection Control & Hospital Epidemiology, 2005